top of page
Top News
rare-genetoic-epilep.png

Living with Dravet Syndrome

First Name

Top News

November 28, 2022

Epygenix Therapeutics to Present at the American Epilepsy Society 2022 Annual Meeting in Nashville

April 25, 2017

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

June 24, 2019

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

July 29, 2019

Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

January 27, 2020

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

September 17, 2020

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

August 02, 2021

Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

August 02, 2021

Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome

August 02, 2021

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

August 30, 2021

Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome

February 16, 2022

Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome

March 15, 2022


Epygenix Therapeutics Announces Appointment of Darren Cline as CEO

bottom of page